Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-01
E
Emily Ward Bivens
Role not yet determined Is this you? Add your title
Also affiliated: University of Tennessee at Knoxville (2025)
1 h-index
4 pubs
2 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Emily Ward Bivens' research focuses on the investigation of therapeutic vaccines for head and neck cancers. She is the principal investigator on a Phase I/II clinical trial evaluating the human papillomavirus therapeutic vaccine, PepCan, aimed at reducing recurrence in patients with head and neck squamous cell carcinoma. This study is a randomized, double-blind, placebo-controlled trial. Bivens collaborates with researchers at the University of Arkansas for Medical Sciences, including David W. Ussery, Michael Scott Robeson, Jennifer L. Faulkner, and Yong‐Chen Lu, with whom she has co-authored publications. Her work in this area is supported by her recent publications in scientific journals.
Metrics
- h-index: 1
- Publications: 4
- Citations: 2
Selected Publications
-
A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence (2026)
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
Collaboration Network
Top Collaborators
Omar Atiq
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Teresa T. Evans
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Milan Bimali
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Jasmine Crane
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Nadia Darwish
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Jennifer L. Faulkner
Winthrop Rockefeller Foundation
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Rangaswamy Govindarajan
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Alongkorn Kurilung
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Oxana P. Lazarenko
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Keanna Marsh
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Intawat Nookaew
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Michael Robeson
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Jumin Sunde
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Emre Vural
University of Arkansas for Medical Sciences
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Mindy Wilman
Winthrop Rockefeller Foundation
2 shared publications
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
- A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence
Similar Researchers
Based on overlapping research topics
Keanna Marsh
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Clinical Research Studies
Teresa T. Evans
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Jennifer L. Faulkner
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Omar Atiq
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Clinical Research Studies
Brad Baltz
Arkansas Colleges of Health Education
Cancer Treatment and Pharmacology
Clinical Research Studies
Immune Response and Inflammation
Gisela F Erf
University of Arkansas at Fayetteville
Immune Response and Inflammation
Microbial infections and disease research
Host-Pathogen Interactions